2017
Recruitment of Underrepresented Minority Researchers into HIV Prevention Research: The HIV Prevention Trials Network Scholars Program
Vermund SH, Hamilton EL, Griffith SB, Jennings L, Dyer TV, Mayer K, Wheeler D. Recruitment of Underrepresented Minority Researchers into HIV Prevention Research: The HIV Prevention Trials Network Scholars Program. AIDS Research And Human Retroviruses 2017, 34: 171-177. PMID: 29145745, PMCID: PMC5806068, DOI: 10.1089/aid.2017.0093.Peer-Reviewed Original ResearchConceptsHIV Prevention Trials NetworkHIV prevention researchRace/ethnicityHIV preventionHispanic MSMHIV researchHealth disparitiesTrials NetworkU.S. epidemicPrevention researchNew research protocolsResearch protocolPeer-reviewed articlesProgram completionBlack womenResearch ConsortiumProtocol teamAdvisory GroupEarly career investigatorsStudy dataMenUnderrepresented minority scientistsMajority race/ethnicityExit surveyScholars Program
2011
Experience in international clinical research: the HIV Prevention Trials Network
Sista ND, Karim Q, Hinson K, Donnell D, Eshleman SH, Vermund SH. Experience in international clinical research: the HIV Prevention Trials Network. Clinical Investigation 2011, 1: 1609-1618. PMID: 22348195, PMCID: PMC3281583, DOI: 10.4155/cli.11.156.Peer-Reviewed Original ResearchHIV Prevention Trials NetworkCombination antiretroviral therapyHIV transmissionClinical trialsPrevention strategiesTrials NetworkHPTN 052 studyOpiate agonist therapySerodiscordant sexual partnersHIV testing ratesPre-exposure prophylaxisHIV prevention strategiesPivotal efficacy trialsInjection drug usersHigh-risk behaviorsPublic health policyAgonist therapyAntiretroviral therapyHIV seroconversionInfected partnerMiddle-income countriesTrial feasibilityAntiretroviral drugsHPTN 068Efficacy trials
2010
Addressing Research Priorities for Prevention of HIV Infection in the United States
Vermund SH, Hodder SL, Justman JE, Koblin BA, Mastro TD, Mayer KH, Wheeler DP, Sadr W. Addressing Research Priorities for Prevention of HIV Infection in the United States. Clinical Infectious Diseases 2010, 50: s149-s155. PMID: 20397942, PMCID: PMC2862583, DOI: 10.1086/651485.Peer-Reviewed Original ResearchConceptsHIV infectionHuman immunodeficiency virusHispanic womenHIV Prevention Trials NetworkNew HIV infectionsClinical Trials GroupName-based reportingHigh rateImmunodeficiency virusAIDS diagnosisTrial groupUS womenInfected personsPrevention estimatesUS populationHealth messagesEthnic minority populationsTrials NetworkDisease controlInfectionWhite womenWomenPreventionNational InstituteMen
2009
Preventing HIV in Developing Countries: Status of Biomedical Interventions
Vermund S. Preventing HIV in Developing Countries: Status of Biomedical Interventions. The FASEB Journal 2009, 23: 199.1-199.1. DOI: 10.1096/fasebj.23.1_supplement.199.1.Peer-Reviewed Original ResearchHIV Prevention Trials NetworkPrevention of motherHIV drug resistanceNeedle exchange programsDNA boostBehavior changeHIV seroconversionHIV seroincidenceEarly therapyPregnant womenHSV-2Clinical trialsHIVMale circumcisionDrug addiction treatmentDrug resistanceTrials NetworkAddiction treatmentBiomedical interventionsSeroincidenceInfantsRisk reductionTherapyPrevention challengesEfficacy
2003
Developing a Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Therapeutic Research Agenda for Resource-Limited Countries: A Consensus Statement
Vermund SH, Powderly WG, Association of IDSA O. Developing a Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Therapeutic Research Agenda for Resource-Limited Countries: A Consensus Statement. Clinical Infectious Diseases 2003, 37: s4-s12. PMID: 12822127, DOI: 10.1086/375367.Peer-Reviewed Original ResearchConceptsResource-limited countriesAntiretroviral therapyResource-limited settingsDelivery of ARTImmunodeficiency syndrome careClinical Trials NetworkHealth care providersResource limited countriesHealth care practitionersHealth care advocatesHIV diseaseHIV/Consensus statementTreatment accessCare providersCare practitionersTrials NetworkART provisionCare advocatesTherapyMillions of peoplePharmaceutical expertsPatient monitoringCommunity representativesDisease